Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SUSAN HILSENBECK and TAO WANG.
Connection Strength

0.624
  1. To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.
    View in: PubMed
    Score: 0.100
  2. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54.
    View in: PubMed
    Score: 0.095
  3. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10.
    View in: PubMed
    Score: 0.082
  4. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13.
    View in: PubMed
    Score: 0.031
  5. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014; 6(9):69.
    View in: PubMed
    Score: 0.030
  6. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
    View in: PubMed
    Score: 0.029
  7. Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.
    View in: PubMed
    Score: 0.029
  8. Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? AJR Am J Roentgenol. 2013 Aug; 201(2):456-61.
    View in: PubMed
    Score: 0.028
  9. Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9.
    View in: PubMed
    Score: 0.028
  10. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.028
  11. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43.
    View in: PubMed
    Score: 0.026
  12. Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.
    View in: PubMed
    Score: 0.025
  13. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
    View in: PubMed
    Score: 0.024
  14. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.024
  15. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.024
  16. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.